{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T05:53:18Z","timestamp":1761544398699,"version":"build-2065373602"},"reference-count":11,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","japha.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Pharmacists Association"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1016\/j.japh.2021.01.021","type":"journal-article","created":{"date-parts":[[2021,2,11]],"date-time":"2021-02-11T09:35:45Z","timestamp":1613036145000},"page":"e152-e155","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Successful application of pharmacogenomic testing in the evaluation and management of a patient with human immunodeficiency virus and disseminated histoplasmosis"],"prefix":"10.1016","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8741-246X","authenticated-orcid":false,"given":"Kevin F.","family":"Hanna","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joshua P.","family":"Havens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara H.","family":"Bares","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.japh.2021.01.021_bib1","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.diagmicrobio.2008.05.006","article-title":"Histoplasmosis in HIV-infected patients in a southern regional medical center: poor prognosis in the era of highly active antiretroviral therapy","volume":"62","author":"Baddley","year":"2008","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"1","key":"10.1016\/j.japh.2021.01.021_bib2","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1086\/379770","article-title":"Histoplasmosis and acquired immunodeficiency syndrome: a study of prognostic factors","volume":"38","author":"Couppi\u00e9","year":"2004","journal-title":"Clin Infect Dis"},{"issue":"7","key":"10.1016\/j.japh.2021.01.021_bib3","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1086\/521259","article-title":"Clinical practice guidelines for the management of patients with histoplasmosis: 2007 update by the infectious diseases society of America","volume":"45","author":"Wheat","year":"2007","journal-title":"Clin Infect Dis"},{"issue":"suppl_1","key":"10.1016\/j.japh.2021.01.021_bib4","doi-asserted-by":"crossref","first-page":"i12","DOI":"10.1093\/jac\/dkx029","article-title":"Therapeutic drug monitoring for invasive mould infections and disease: pharmacokinetic and pharmacodynamic considerations","volume":"72","author":"Stott","year":"2017","journal-title":"J\u00a0Antimicrob Chemother"},{"issue":"7","key":"10.1016\/j.japh.2021.01.021_bib5","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1002\/phar.1400","article-title":"CYP2C19 polymorphisms and therapeutic drug monitoring of voriconazole: are we ready for clinical implementation of pharmacogenomics?","volume":"34","author":"Owusu Obeng","year":"2014","journal-title":"Pharmacotherapy"},{"issue":"5","key":"10.1016\/j.japh.2021.01.021_bib6","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1097\/FPC.0000000000000277","article-title":"Impact of the CYP2C19 genotype on voriconazole exposure in adults with invasive fungal infections","volume":"27","author":"Hamadeh","year":"2017","journal-title":"Pharmacogenet Genomics"},{"issue":"2","key":"10.1016\/j.japh.2021.01.021_bib7","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.ijantimicag.2015.12.003","article-title":"Impact of CYP2C19 genetic polymorphisms on voriconazole dosing and exposure in adult patients with invasive fungal infections","volume":"47","author":"Lamoureux","year":"2016","journal-title":"Int J Antimicrob Agents"},{"issue":"1","key":"10.1016\/j.japh.2021.01.021_bib8","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1097\/FTD.0b013e31820530cd","article-title":"Modulators of very low voriconazole concentrations in routine therapeutic drug monitoring","volume":"33","author":"Hassan","year":"2011","journal-title":"Ther Drug Monit"},{"issue":"1","key":"10.1016\/j.japh.2021.01.021_bib9","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1002\/cpt.583","article-title":"Clinical pharmacogenetics implementation consortium (CPIC) guidelines for CYP2C19 and voriconazole therapy","volume":"102","author":"Moriyama","year":"2017","journal-title":"Clin Pharmacol Ther"},{"issue":"10","key":"10.1016\/j.japh.2021.01.021_bib10","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1086\/598327","article-title":"Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agents","volume":"48","author":"Br\u00fcggemann","year":"2009","journal-title":"Clin Infect Dis"},{"issue":"2","key":"10.1016\/j.japh.2021.01.021_bib11","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1124\/dmd.32.2.267","article-title":"Identification of human UDP-glucuronosyltransferase enzyme(s) responsible for the glucuronidation of posaconazole (Noxafil)","volume":"32","author":"Ghosal","year":"2004","journal-title":"Drug Metab Dispos"}],"container-title":["Journal of the American Pharmacists Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1544319121000236?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1544319121000236?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T05:47:39Z","timestamp":1761544059000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1544319121000236"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":11,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["S1544319121000236"],"URL":"https:\/\/doi.org\/10.1016\/j.japh.2021.01.021","relation":{},"ISSN":["1544-3191"],"issn-type":[{"type":"print","value":"1544-3191"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Successful application of pharmacogenomic testing in the evaluation and management of a patient with human immunodeficiency virus and disseminated histoplasmosis","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Pharmacists Association","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.japh.2021.01.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 American Pharmacists Association\u00ae. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}